Table 2. AD surface densities and mole fractions in the bilayer and the actual aqueous concentrations required to double the fluorescence quench rate.
| Estimated usingK1 | Estimated using cLogP | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| AD | DAD | LogK1 | cLogP | {AD}L | mAD | [AD]W | {AD}L | mAD | [AD]W |
| μM | moles/cm2 | μM | moles/cm2 | μM | |||||
| Fluoxetine | 17 | 3.61 | 4.27 | 5.5⋅10−12 | 0.023 | 8.7 | 9.0⋅10−12 | 0.037 | 3.5 |
| Paroxetine | 30 | 3.35 | 3.68 | 6.7⋅10−12 | 0.028 | 20 | 9.7⋅10−12 | 0.040 | 15 |
| Sertraline | 31 | 4.51 | 5.18 | 17⋅10−12 | 0.068 | 5.4 | 20⋅10−12 | 0.078 | 1.6 |
| Amitriptyline | 53 | 3.59 | 4.72 | 14⋅10−12 | 0.056 | 32 | 29⋅10−12 | 0.11 | 9.0 |
| Imipramine | 82 | 3.31 | 3.71 | 14⋅10−12 | 0.057 | 61 | 21⋅10−12 | 0.084 | 50 |
| Fluvoxamine | 84 | 2.61 | 3.04 | 5.0⋅10−12 | 0.021 | 76 | 9.9⋅10−12 | 0.041 | 69 |
| Alaproclate | 220 | 2.43 | 2.58 | 8.0⋅10−12 | 0.033 | 210 | 10⋅10−12 | 0.042 | 200 |
| Citalopram | 250 | 2.64 | 3.39 | 12⋅10−12 | 0.050 | 230 | 30⋅10−12 | 0.12 | 200 |
| Zimelidine | 290 | 2.40 | 3.69 | 9.3⋅10−12 | 0.039 | 280 | 24⋅10−12 | 0.092 | 250 |
| Clomipramine | 39 | 5.29 | 25⋅10−12 | 0.096 | 1.7 | ||||
| Lofepramine | 42 | 6.26 | 28⋅10−12 | 0.11 | 0.2 | ||||
| Protriptyline | 52 | 4.70 | 29⋅10−12 | 0.11 | 9.0 | ||||
| Nortriptyline | 61 | 4.76 | 33⋅10−12 | 0.13 | 11 | ||||
| Trimipramine | 72 | 4.98 | 41⋅10−12 | 0.15 | 10 | ||||
| Dothiepin | 83 | 4.65 | 41⋅10−12 | 0.15 | 22 | ||||
| Desipramine | 97 | 4.28 | 37⋅10−12 | 0.14 | 41 | ||||
| Doxepin | 160 | 4.27 | 50⋅10−12 | 0.18 | 85 | ||||
{AD}L, mAD and [AD]W were calculated from Eqs. S29–S31 using either the experimental () or estimated () adsorption coefficients, where cLogP is the consensus value from the ACD/Percepta PhysChem Suite. = 1.5 ml, = 37.3 μmol, = 0.7 nm2, d0 (the DC22:1PC bilayer phosphate to phosphate thickness, 4.5 nm; Lewis and Engelman, 1983), and = 0.3 nm2.